Frontier Capital Management Co. LLC Sells 3,058 Shares of Pacira Pharmaceuticals, Inc. (PCRX)
Frontier Capital Management Co. LLC cut its position in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 2.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 123,857 shares of the company’s stock after selling 3,058 shares during the period. Frontier Capital Management Co. LLC owned 0.31% of Pacira Pharmaceuticals worth $5,908,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in PCRX. Benjamin F. Edwards & Company Inc. boosted its position in shares of Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock worth $114,000 after buying an additional 1,149 shares during the last quarter. FNY Partners Fund LP acquired a new position in shares of Pacira Pharmaceuticals during the first quarter worth about $136,000. Ameritas Investment Partners Inc. acquired a new position in shares of Pacira Pharmaceuticals during the first quarter worth about $144,000. Schnieders Capital Management LLC acquired a new position in shares of Pacira Pharmaceuticals during the second quarter worth about $201,000. Finally, Amalgamated Bank acquired a new position in shares of Pacira Pharmaceuticals during the first quarter worth about $204,000.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) opened at 36.00 on Thursday. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.95 and a 52-week high of $58.95. The company’s 50-day moving average is $42.22 and its 200-day moving average is $45.17. The firm’s market capitalization is $1.45 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The company had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. During the same quarter in the prior year, the business earned $0.21 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Analysts forecast that Pacira Pharmaceuticals, Inc. will post ($0.13) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/24/frontier-capital-management-co-llc-sells-3058-shares-of-pacira-pharmaceuticals-inc-pcrx.html.
A number of brokerages have recently weighed in on PCRX. Wedbush reissued an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 19th. Canaccord Genuity reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Pacira Pharmaceuticals in a research report on Monday, July 31st. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Mizuho reaffirmed a “buy” rating and issued a $53.00 price objective (down from $54.00) on shares of Pacira Pharmaceuticals in a research report on Tuesday. Finally, BMO Capital Markets cut their price objective on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating on the stock in a research report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $53.92.
In other news, CAO Kristen Marie Williams sold 3,461 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the transaction, the chief accounting officer now owns 21,312 shares in the company, valued at $783,216. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Lauren Bullaro Riker sold 601 shares of the firm’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $26,035.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,869 shares of company stock valued at $1,590,276. Corporate insiders own 6.60% of the company’s stock.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).
Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.